Incyte (INCY) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.25% |
| Dec 31, 2025 | 6.55% |
| Sep 30, 2025 | 7.06% |
| Jun 30, 2025 | 6.89% |
| Mar 31, 2025 | 7.48% |
| Dec 31, 2024 | 11.28% |
| Sep 30, 2024 | 12.42% |
| Jun 30, 2024 | 6.89% |
| Mar 31, 2024 | 8.04% |
| Dec 31, 2023 | 9.91% |
| Sep 30, 2023 | 4.78% |
| Jun 30, 2023 | 8.30% |
| Mar 31, 2023 | 8.06% |
| Dec 31, 2022 | 9.31% |
| Sep 30, 2022 | 5.40% |
| Jun 30, 2022 | 6.59% |
| Mar 31, 2022 | 7.46% |
| Dec 31, 2021 | 11.81% |
| Sep 30, 2021 | 10.01% |
| Jun 30, 2021 | 16.03% |
| Mar 31, 2021 | 17.89% |
| Dec 31, 2020 | 21.49% |
| Sep 30, 2020 | 20.00% |
| Jun 30, 2020 | 21.34% |
| Mar 31, 2020 | 19.35% |
| Dec 31, 2019 | 21.45% |
| Sep 30, 2019 | 22.87% |
| Jun 30, 2019 | 21.24% |
| Mar 31, 2019 | 21.48% |
| Dec 31, 2018 | 30.72% |
| Sep 30, 2018 | 31.95% |
| Jun 30, 2018 | 29.89% |
| Mar 31, 2018 | 31.54% |
| Dec 31, 2017 | 30.07% |
| Sep 30, 2017 | 29.72% |
| Jun 30, 2017 | 27.84% |
| Mar 31, 2017 | 25.24% |
| Dec 31, 2016 | 29.83% |
| Sep 30, 2016 | 29.06% |
| Jun 30, 2016 | 24.23% |
| Mar 31, 2016 | 24.69% |
| Dec 31, 2015 | 32.64% |
| Sep 30, 2015 | 33.83% |
| Jun 30, 2015 | 37.35% |
| Mar 31, 2015 | 41.27% |